Red Light Holland Psilocybin Truffles, Sold in The Netherlands, Complete Second Evaluation Under a Health Canada Approved cGMP Laboratory Post published:January 6, 2022 Post category:Press Release
Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee Post published:January 6, 2022 Post category:Press Release
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies Post published:January 6, 2022 Post category:Press Release
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines Post published:January 5, 2022 Post category:Press Release
PharmaTher Announces Publication of Research Data for KETABET™ Post published:January 4, 2022 Post category:Press Release
Filament Health Announces Health Canada Approval for Phase II Trial Administering New Psilocybin Microdose Formulation Post published:January 4, 2022 Post category:Press Release
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders Post published:January 4, 2022 Post category:Press Release
MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway Post published:January 4, 2022 Post category:Press Release
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC Post published:January 4, 2022 Post category:Press Release
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology Post published:January 4, 2022 Post category:Press Release